sabatolimab + decitabine

Sabatolimab + decitabine is a combination therapy under investigation for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). **Sabatolimab** is a high-affinity, humanized IgG4 monoclonal antibody that targets and blocks the immune checkpoint receptor T cell immunoglobulin domain and mucin domain-3 (TIM-3), expressed on leukemic stem cells and immune cells, modulating both innate and adaptive immunity[1][3]. **Decitabine** is a cytidine deoxynucleoside analogue and hypomethylating agent that selectively inhibits DNA methyltransferases at low doses, resulting in DNA hypomethylation and reactivation of silenced genes important for cellular differentiation[8]. The combination aims to provide synergistic antitumor activity—decitabine acting as an epigenetic modulator and sabatolimab enhancing immune response against malignant cells. The regimen has shown a tolerable safety profile in clinical studies, with response rates consistent with HMAs in high-risk MDS[3]. Main indications under investigation are intermediate-, high-, and very-high-risk MDS and newly diagnosed AML[1][3].

Other names

sabatolimab + decitabineMBG453 + decitabine